1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCXW
Carmell Therapeutics CorporationUS flagNASDAQ Capital Market
0.03
USD
-0.02
- -
558,174.00Market Cap
Carmell Therapeutics Corporation
CTCXW
(NASDAQ Capital Market)

Recent

price

0.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
-9,933.82
-9,933.82
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
-6
-9
-15
-10
-10
Net Income, GAAP
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-20,605.47
-20,605.47
Profit Margin (%)
-16
-7
24
-5
-5
Working Capital
1
1
1
- -
- -
LT Debt
-30
-38
25
-5
-5
Total Equity
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
29
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
4
2
1
Cash, Cash Equivalents & STI
2
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
6
6
Payables & Accruals
5
6
6
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-119.04%
Free Cash Flow
- -
- -
-47.62%
Net Income, GAAP
- -
- -
-32.87%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
-4
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Innovent Biologics, Inc. (IVBXF)
Ikena Oncology, Inc. (IKNA)
Aptorum Group Limited (APM)
PharmaCyte Biotech, Inc. (PMCB)
Cannassure Therapeutics Ltd (CSURE.TA)
Apex Biotechnology Corp. (1733.TW)
Business
Carmell Therapeutics Corporation, which has since transitioned its operations and rebranded as Longevity Health Holdings, currently concentrates on developing advanced bio-aesthetic solutions for enhancing skin and hair vitality. This enterprise leverages its proprietary Carmell Secretome, a rich blend of over a thousand growth factors and proteins carefully extracted from allogeneic human platelets, to stimulate natural regenerative pathways. The company’s portfolio encompasses various skincare and topical haircare product lines, including formulations designed for anti-aging, post-procedure recovery, and specialized skin and hair health applications. An innovative microemulsion delivery system is also employed to provide active ingredients without the use of many common, potentially irritating excipients. Established in 2008, the company maintains its operational roots in Pittsburgh, Pennsylvania.